Article
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2016
Pouessel D, Neuzillet Y, Mertens L S, van der Heijden M S, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst C D, Tomlinson D C, Harnden P, Bostrom P J, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat S F, Sagalowsky A I, Ashfaq R, Burger M, Jewett M A S, Zlotta A R, Broeks A, Bapat B, Knowles M A, Lotan Y, van der Kwast T H, Culine S, Allory Y, van Rhijn B W G
Abstract excerpt
BACKGROUND: Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor growth, suggesting that this tyrosine kinase receptor is a candidate for personalized bladder cancer treatment, particularly in patients with mutated FGFR3. We addressed tumor heterogeneity in a large multicenter, multi-laboratory study, as this may...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.